Cancer immunotherapy has transformed oncology, yet a substantial proportion of patients fail to respond — and understanding why remains one of the field's most pressing challenges. A growing body of evidence points to dendritic cells (DCs), the immune system's master antigen presenters, as central players in whether tumors are recognized and destroyed or silently tolerated. This review illuminates how DC heterogeneity and functional collapse within the tumor microenvironment may be quietly undermining therapies that billions of dollars and decades of research have built.
The analysis maps the functional landscape of distinct DC subsets — including conventional DC1s, DC2s, and plasmacytoid DCs — within the tumor microenvironment. Critically, it details how tumors exploit signaling pathways and immunosuppressive mediators to induce DC exhaustion, impair antigen cross-presentation, and skew DC polarization toward tolerogenic states that actively suppress anti-tumor immunity. Rather than DCs failing passively, the review argues they are actively co-opted, blunting both checkpoint inhibitor and adoptive cell therapies.
This framing carries meaningful implications for the immunotherapy field. Standard checkpoint blockade targets T-cell inhibitory axes, but if upstream DC dysfunction prevents adequate tumor antigen presentation in the first place, downstream T-cell activation may remain insufficient regardless of checkpoint status. The review's value lies in positioning DC restoration — through targeted agonists, DC-based vaccines, or combination strategies — as a rational adjunct to existing regimens. However, this is a review article rather than a primary clinical trial, meaning its conclusions synthesize existing literature rather than generate new causal data. The heterogeneity of DC biology across tumor types also complicates generalization. Nonetheless, for researchers and clinicians frustrated by immunotherapy non-responders, the DC axis represents an underexplored and potentially actionable therapeutic frontier.